RJN Posted April 6, 2022 Share Posted April 6, 2022 A new drug application for adagrasib was accepted by the FDA for the treatment of patients with KRAS G12C–mutated non–small cell lung cancer. The FDA has accepted a new drug application (NDA) for adagrasib (MRTX 849) as treatment for patients with previously treated KRAS G12C–positive non–small cell lung cancer (NSCLC), according to a press release from drug developer Mirati Therapeutics.1 Adagrasib is being assessed by the FDA for accelerated approval, which is designated for drugs capable of treating serious conditions and for fulfilling unmet medical needs based on a surrogate end point. The application is also being reviewed under the FDA Real-Time Oncology Review pilot program, which could result in a more efficient review process that would allow more safe and effective treatments to be made more readily available. Adagrasib has a prescription drug action date of December 14, 2022. “KRAS mutations have been notoriously hard to target and historically have had limited therapeutic options. The KRAS G12C biomarker in particular is associated with poor survival outcomes. The FDA's review of the adagrasib NDA marks important progress toward potentially providing a new, targeted option for those living with KRAS G12C-mutated [NSCLC],” investigator Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said in a press release. Adagrasib most recently earned a breakthrough therapy designation from the FDA for patients with KRAS G12C–mutant NSCLC in June 2021 based on findings from the phase 2 KRYSTAL-1 trial (NCT03785249).2 Patients in the intent-to-treat arm who received a 600 mg dose of adagrasib twice daily experienced an overall response rate of 43% and a disease control rate of 80% by central independent review.3 The study had a median follow-up of 9.0 months. The ongoing, confirmatory phase 3 KRYSTAL-12 trial is evaluating the use of second-line adagrasib compared with docetaxel in patients with KRAS G12C–mutated NSCLC. “The acceptance of our NDA for adagrasib is a significant step forward in Mirati's ongoing efforts to advance innovative, differentiated treatment options for patients with KRAS G12C cancers,” Charles Baum, MD, PhD, president, founder, and head of research and development at Mirati Therapeutics, Inc, concluded. “We look forward to working with the FDA during their review of our application and potentially provide a novel option for patients with [NSCLC].” Results from the KRYSTAL-1 study will be presented at an upcoming medical conference in the first half of 2022. References U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics' new drug application for adagrasib as treatment of previously treated KRAS G12C-mutated non–small cell lung cancer. News release. Mirati Therapeutics. February 15, 2022. Accessed February 16. 2022. https://bit.ly/3LBVKTt Mirati Therapeutics’ adagrasib receives breakthrough therapy designation from U.S. Food and Drug Administration for patients with advanced non–small cell lung cancer harboring the KRAS G12C mutation. News release. Mirati Therapeutics. June 24, 2021. Accessed February 16, 2022. https://bit.ly/3xQXksJ Mirati Therapeutics announces positive phase 2 topline results for investigational adagrasib in patients with KRAS G12C-mutated advanced non–small cell lung cancer. News release. Mirati Therapeutics, Inc. September 20, 2021. Accessed February 16, 2022. https://bit.ly/3zoRpLZ Related Content: Non-Small Cell Lung Cancer (NSCLC) First-Line TKI Plus Up-Front Local Radiotherapy Improves Survival in EGFR+ NSCLC OncView™ Podcast: Immunotherapy Response Monitoring in Lung Cancer Esophageal-Sparing Intensity-Modulated Radiotherapy Improves Symptomatic Esophagitis in Advanced NSCLC First-Line TKI Plus Up-Front Local Radiotherapy Improves Survival in EGFR+ NSCLC April 1, 2022 Ariana Pelosci Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy. Adding up-front local radiotherapy to a first-line tyrosine kinase inhibitor (TKIs) improved progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutated non–small cell lung cancer, according to the results of the phase 3 SINADS trial (NCT02893332). The pre-specified interim analysis found patients who were receiving only TKIs had a median PFS of 12.5 months (95% CI, 11.6-13.4) vs 20.2 months (95% CI, 17.9-22.5) for those receiving TKIs plus radiotherapy (HR, 0.22; 95% CI, 0.17-0.46; P <.001). The median OS for the TKI group was 17.6 months (95% CI, 15.4-19.8) vs 25.5 months (95% CI, 23.2-27.8) for the TKI plus radiotherapy group (HR, 0.44; 95% CI, 0.28-0.68; P <.001). A total of 133 patients were randomized to either the TKI-only group (n = 65) or the TKI plus radiotherapy group (n = 68). Because of the results from this analysis, the ethics committee did not recommend additional recruitment for the trial. The cutoff for treatment was 1 year, and the median follow-up was 23.6 months. In terms of patient characteristics, 73.1% of patients in the TKI group had bone metastases vs 68.9% in the TKI plus radiotherapy group. Other areas of oligometastatic lesions included the abdomen (18.8% vs 18.0%) and the contralateral lung (6.9% vs 9.6%). Ninety-two patients had an EGFR abnormality in exon 19. Additionally, investigators more commonly treated patients with gefitinib (52.6%) and erlotinib (39.8%) vs icotinib. The most common radiotherapy doses included 30 Gy in 53.5% of fields, and 25 Gy in 31.0% of fields. In 36 patients in the TKI group vs 62 in the TKI plus radiotherapy, local control of primary tumor and metastases was achieved at the last follow-up (P <.001). The 6-month PFS rate was 95.2% (95% CI, 93.6%-96.9%) in the TKI group and 99.1% (95% CI, 98.7-99.5%) in the TKI plus radiotherapy group (P >.05). At the time this analysis was conducted, 93 patients had died. Additionally, 38 patients in the TKI-only arm underwent palliative radiotherapy to manage symptoms, 6 of whom underwent radiofrequency ablation. The post-hoc analysis identified several independent predictors of PFS, including Zurbod performance status (P = .02), number of metastases (P = .004), and radiotherapy (P = .005). Additionally, the independent factor of OS included Zubrod performance status (P = .02), T stage (P = .02), number of metastases (P = .004), mutation type (P = .001), and radiotherapy (P = .004). Adverse effects relating to TKI treatment included skin reactions in both groups. Three patients in the TKI-only group and 5 in the TKI plus radiotherapy group required dose reductions, with 1 and 2 patients in both respective groups discontinuing treatment. Grade 3/4 skin toxicity was reported in 10 patients in the TKI group and 8 patients also developed grade 3/4 pruritus. Among those in the TKI plus radiotherapy group, 10 patients developed grade 3/4 skin rash, and 5 patients had grade 3/4 pneumonitis. Moreover, 1 patient had a fractured rib that was attributed to chest radiotherapy. Two patients needed long-term pain management after receiving radiotherapy, with 1 patient having nephrolithiasis, and the other having herpes zoster that was deemed unrelated to treatment. Reference Wang XS, Bai YF, Verma V, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. Published Online January 30, 2022. doi:10.1093/jnci/djac015 Related Content: Non-Small Cell Lung Cancer (NSCLC) Esophageal-Sparing Intensity-Modulated Radiotherapy Improves Symptomatic Esophagitis in Advanced NSCLC FDA Issues Complete Response Letter for Sintilimab Plus Chemo in First-Line Treatment of Nonsquamous NSCLC FDA Approves FoundationOne CDx in NSCLC Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.